Lundbeck Epilepsy Research Featured in Report on Neurological Disorders
Lundbeck’s epilepsy commitment includes long-term research, education and
DEERFIELD, Ill. -- August 29, 2013
Lundbeck’s epilepsy research efforts are featured in a new report on
neurological disorders from the Pharmaceutical Research and Manufacturers of
America (PhRMA). The report is accompanied by an educational video about the
science of epilepsy, including the role of neuroinflammation and how a better
understanding of the neuroinflammatory processes may yield new seizure
therapies. The video can be viewed here.
The video features three scientists from Lundbeck’s US research organization.
Lundbeck researchers in the U.S. focus entirely on brain disorders, exploring
the role of neuroinflammation in conditions including Alzheimer’s disease,
depression, Parkinson’s disease, schizophrenia, epilepsy and others.
“Almost every neurological disease that has been studied has been shown to
have some component of neuroinflammation,” said Stevin Zorn, PhD, executive
vice president of Lundbeck Research USA. “By studying neuroinflammation
biologies, we’re hoping to identify new ways to treat complicated neurological
disorders like epilepsy and related seizure disorders. While this research has
a ways to go before reaching the bedside, it has the potential to play an
important role in the future treatment of epilepsy.”
Partnering to Make a Difference in Epilepsy
In addition to its own R&D efforts, Lundbeck supports the scientific and
professional epilepsy community to accelerate research and education. Since
2011, Lundbeck has supported more than 120 continuing medical education
initiatives – including multiple J. Kiffin Penry programs – and has provided
ongoing support for numerous investigator-initiated clinical trials. In
addition, to help seed tomorrow’s leading brain researchers, Lundbeck partners
with academic institutions that focus on brain-related research. For instance,
Lundbeck hosts student interns from several universities such as Drew
University, Madison, NJ, one of the few liberal arts colleges with an
undergraduate neuroscience program, and has donated high tech equipment
including a nuclear magnetic resonance (NMR) spectrometer to the school to
advance its students’ education to enable hands-on learning with cutting edge
At the core of Lundbeck’s work is support and partnership in the patient
community. For instance, Studio E: The Epilepsy Art Therapy Program is made
possible through a partnership between Lundbeck, the Epilepsy Foundation and
more than 30 of its local affiliates nationwide. Lundbeck also partners with
the Lennox-Gastaut Syndrome Foundation to fund a scholarship allowing many
families to attend the organization’s annual Family & Professional Conference,
and supports all of the Tuberous Sclerosis Alliance’s local walks and
educational programs. Our employees are inspired by actively participating in
hundreds of epilepsy events each year.
“Seeing the person behind the disease is at the core of everything we do at
Lundbeck – from early-stage research and drug development to our interactions
with professionals, patients and their families,” said Daniel Brennan, vice
president and general manager of the neurology business at Lundbeck. “This is
why we are so active not only in partnering with professionals, but also
advocacy groups, people with challenging seizure disorders and their
caregivers. This engagement is what educates and motivates us to do our best
work every day.”
Learn more about Lundbeck’s epilepsy support and programs at
About Lundbeck in the U.S.
A wholly owned subsidiary of H. Lundbeck A/S in Denmark, Lundbeck U.S. is
headquartered in Deerfield, Illinois,and is committed to providing
innovativespecialty therapies that fulfill unmet medical needs of people with
brain disorders. In its research late-stage research pipeline, the company has
neurology compounds under investigation for Alzheimer’s disease, stroke and
epilepsy, in addition to therapies in development for mental health disorders.
Lundbeck is a global pharmaceutical company highly committed to improving the
quality of life of people living with brain diseases. For this purpose,
Lundbeck is engaged in the entire value chain throughout research,
development, production, marketing and sales of pharmaceuticals across the
world. The company’s products are targeted at disorders such as depression and
anxiety, psychotic disorders, epilepsy, Huntington’s, Alzheimer’s and
Parkinson’s diseases. Lundbeck’s pipeline consists of several mid- to
late-stage development programs.
Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in
Denmark. We have employees in 57 countries and our products are registered in
more than 100 countries. We have research centers in Denmark, China and the
United States and production facilities in Italy, France, Mexico, China and
Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012.
Lundbeck’s shares are listed on the stock exchange in Copenhagen under the
symbol ”LUN.” Lundbeck has a sponsored Level 1 ADR programme listed in the US
(OTC) under the symbol ”HLUYY.” For additional information, we encourage you
to visit our corporate site www.lundbeck.com.
Lundbeck Media contact:
Matt Flesch, (847) 282-1154; (847) 922-2871 (cell)
Press spacebar to pause and continue. Press esc to stop.